Cargando…
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches
The recent success of checkpoint blockade has highlighted the potential of immunotherapy approaches for cancer treatment. Although the majority of approved immunotherapy drugs target T cell subsets, it is appreciated that other components of the immune system have important roles in tumor immune sur...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838611/ https://www.ncbi.nlm.nih.gov/pubmed/27148271 http://dx.doi.org/10.3389/fimmu.2016.00152 |
_version_ | 1782427997889888256 |
---|---|
author | Carotta, Sebastian |
author_facet | Carotta, Sebastian |
author_sort | Carotta, Sebastian |
collection | PubMed |
description | The recent success of checkpoint blockade has highlighted the potential of immunotherapy approaches for cancer treatment. Although the majority of approved immunotherapy drugs target T cell subsets, it is appreciated that other components of the immune system have important roles in tumor immune surveillance as well and thus represent promising additional targets for immunotherapy. Natural killer (NK) cells are the body’s first line of defense against infected or transformed cells, as they kill target cells in an antigen-independent manner. Although several studies have clearly demonstrated the active role of NK cells in cancer immune surveillance, only few clinically approved therapies currently exist that harness their potential. Our increased understanding of NK cell biology over the past few years has renewed the interest in NK cell-based anticancer therapies, which has lead to a steady increase of NK cell-based clinical and preclinical trials. Here, the role of NK cells in cancer immune surveillance is summarized, and several novel approaches to enhance NK cell cytotoxicity against cancer are discussed. |
format | Online Article Text |
id | pubmed-4838611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48386112016-05-04 Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches Carotta, Sebastian Front Immunol Immunology The recent success of checkpoint blockade has highlighted the potential of immunotherapy approaches for cancer treatment. Although the majority of approved immunotherapy drugs target T cell subsets, it is appreciated that other components of the immune system have important roles in tumor immune surveillance as well and thus represent promising additional targets for immunotherapy. Natural killer (NK) cells are the body’s first line of defense against infected or transformed cells, as they kill target cells in an antigen-independent manner. Although several studies have clearly demonstrated the active role of NK cells in cancer immune surveillance, only few clinically approved therapies currently exist that harness their potential. Our increased understanding of NK cell biology over the past few years has renewed the interest in NK cell-based anticancer therapies, which has lead to a steady increase of NK cell-based clinical and preclinical trials. Here, the role of NK cells in cancer immune surveillance is summarized, and several novel approaches to enhance NK cell cytotoxicity against cancer are discussed. Frontiers Media S.A. 2016-04-21 /pmc/articles/PMC4838611/ /pubmed/27148271 http://dx.doi.org/10.3389/fimmu.2016.00152 Text en Copyright © 2016 Carotta. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Carotta, Sebastian Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches |
title | Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches |
title_full | Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches |
title_fullStr | Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches |
title_full_unstemmed | Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches |
title_short | Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches |
title_sort | targeting nk cells for anticancer immunotherapy: clinical and preclinical approaches |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838611/ https://www.ncbi.nlm.nih.gov/pubmed/27148271 http://dx.doi.org/10.3389/fimmu.2016.00152 |
work_keys_str_mv | AT carottasebastian targetingnkcellsforanticancerimmunotherapyclinicalandpreclinicalapproaches |